MYELOME CANADA

MYELOME CANADA

April 01, 2005 11:17 ET

Quebec Drug Hunter to address new Multiple Myeloma Canada

Attention: Assignment Editor, City Editor, Health/Medical Editor, News Editor MONTREAL, QUEBEC--(CCNMatthews - April 1, 2005) - Julian Adams, Quebec City-born organic chemist and drug pioneer will meet with members of newly formed Multiple Myeloma Canada and the media on April 1, 2005 at 2:30 p.m. the Centre Sheraton, to describe his work in the discovery of a breakthrough treatment of myeloma.

WHO: Dr. Julian Adams, Chief Scientific Officer of Boston-based Infinity Pharmaceuticals, Inc., a McGill University Scholar, and Ph.D. Massachusetts Institute of Technology. Discoverer of bortezomib.
WHAT: Discusses his discovery of bortezomib proteasome inhibitor, a Nobel-Prize winning class of anticancer agents. Bortezomib is the first treatment in a decade for multiple myeloma, a cancer of the bone marrow. Open to media interviews with Dr. Adams and with myeloma patients.
WHERE: Centre Sheraton, 1201 Boulevard Rene-Levesque West, Salon 8, 4th Floor.

WHEN: Friday, April 1, 2005 at 2:30 p.m.

BACKGROUND: Multiple myeloma is a rare and incurable blood cancer, with 1,850 new cases being diagnosed in Canada every year. It is estimated that there are roughly 6,000 Canadians at any one time living with multiple myeloma.

Dr. Adams has received many awards, including the 2001 Ribbon of Hope Award for bortezomib (VELCADE‚) from the International Myeloma Foundation. He holds over fifty patents, has authored more than a hundred papers and book chapters in peer-reviewed journals, and has several breakthrough drugs to his credit.

Multiple Myeloma Canada is a non-profit organization created by and for people living with multiple myeloma. What began with one Toronto-based support group in 1996 now includes almost a dozen local groups across Canada, joined to form a national resource network of dedicated volunteers. The goal of Multiple Myeloma Canada is to provide educational resources and emotional support to patients, families, and caregivers; increase awareness of the disease and its effects on the lives of patients and families; promote clinical research and access to new drugs and trials in Canada; advocate for improved access to new therapies, treatment options, and health care resources.
/For further information: Aldo Del Col, Patient and Spokesperson, Multiple Myeloma Canada Tel:514-833-2536 info@myelomacanada.ca www.myelomacanada.ca/ IN: HEALTH

Contact Information